Though the company's founders played a crucial role in the development of the first artificial lumbar disc replacements, LDR has itself always taken a somewhat conrtrarian view toward the promise of lumbar disc replacement. Rather the company is betting on the promise of cervical discs, while rounding out its lumbar line with more traditional fusion approaches.
by David Cassak
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
